Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO

Published:2017-05 Issue:3 Volume:57 Page:303-310.e2
ISSN:1544-3191
Container-title:Journal of the American Pharmacists Association
language:en
Short-container-title:Journal of the American Pharmacists Association

Author:

Haque Reina,Shi Jiaxiao,Chung Joanie,Xu Xiaoqing,Avila Chantal,Campbell Christopher,Ahmed Syed A.,Chen Lei,Schottinger Joanne E.

Funder

Novartis

Publisher

Elsevier BV

Subject

Pharmacology,Pharmacy,Pharmacology (nursing)

Reference20 articles.

1. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia;O'Brien;J Natl Compr Canc Netw,2011

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia;Ganesan;Am J Hematol,2011

4. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms;Bisen;Adv Exp Med Biol,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China;Medicine;2023-12-15

3. Comparison of Clinicopathological Parameters, and Treatment Responses in Younger and Older Chronic Myeloid Leukaemia Patients Treated with Imatinib;NOVEMBER 2023;2023-11-13

4. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights;Cells;2023-06-23

5. Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication;Current Hematologic Malignancy Reports;2022-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3